- Newsletter
- April 2024
Global
From €1010EUR$1,119USD£898GBP
- Report
- November 2023
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- December 2023
- 150 Pages
Global
From €3512EUR$3,633USD£3,017GBP
€5018EUR$5,190USD£4,310GBP
- Report
- February 2024
- 110 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Clinical Trials
- April 2024
- 150 Pages
Global
From €2900EUR$3,000USD£2,491GBP
- Report
- November 2023
- 230 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- November 2023
- 432 Pages
Global
From €9185EUR$9,500USD£7,889GBP
- Report
- January 2021
- 600 Pages
United States
From €2707EUR$2,800USD£2,325GBP
- Report
- November 2020
- 90 Pages
Global
From €5752EUR$5,950USD£4,941GBP
- Report
- November 2020
- 124 Pages
Global
From €928EUR$960USD£797GBP
€1160EUR$1,200USD£997GBP
- Report
- March 2024
- 150 Pages
From €5018EUR$5,190USD£4,310GBP
- Report
- January 2022
- 160 Pages
Global
From €9185EUR$9,500USD£7,889GBP
- Clinical Trials
- November 2020
- 40 Pages
Global
From €1450EUR$1,500USD£1,246GBP
- Report
- June 2020
- 200 Pages
Global
From €6719EUR$6,950USD£5,771GBP
- Drug Pipelines
- January 2018
- 18 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Drug Pipelines
- January 2018
- 17 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Report
- March 2021
- 94 Pages
Global
€21269EUR$22,000USD£18,269GBP
- Drug Pipelines
- January 2018
- 19 Pages
Global
From €9668EUR$10,000USD£8,304GBP
- Report
- August 2019
- 212 Pages
Global
From €10630EUR$10,995USD£9,130GBP
- Report
- January 2021
- 124 Pages
Global
From €3480EUR$3,600USD£2,990GBP
Enzalutamide is a drug used to treat prostate cancer. It is a type of androgen receptor inhibitor, which works by blocking the action of male hormones that can cause the growth of prostate cancer cells. Enzalutamide is used in combination with other treatments, such as hormone therapy, chemotherapy, and radiation therapy. It is typically prescribed to men with advanced prostate cancer that has spread to other parts of the body. Enzalutamide can help slow the progression of the disease and improve quality of life.
Enzalutamide is available in both oral and injectable forms. It is generally well-tolerated, with the most common side effects being fatigue, hot flashes, and joint pain. It is important to note that Enzalutamide can cause serious side effects, including seizures, liver damage, and an increased risk of stroke.
Several companies are involved in the Enzalutamide market, including Astellas Pharma, Pfizer, and AstraZeneca. These companies manufacture and distribute the drug, as well as provide support services for patients. Show Less Read more